共 1 条
- [1] Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 129676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803 EUROPEAN JOURNAL OF CANCER, 2011, 47 (07) : 990 - 996